A Phase 1 interventional study of MK-2214 and Placebo in Alzheimer Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2022, is one of 18 in phase 1, and was the 26th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 8 more countries
Ages 50–85
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 9 · Phase 3 4
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 34 across the 29 interventional studies, 11 across the 1 observational. Of the 29 that completed or were terminated, 20 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease. The primary hypothesis (Part 1) is that at a generally well-tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar
As specified by Phase 1 flexible language in the protocol, modifications to the dose or dosing regimen could be made to achieve the scientific goals of the trial objectives and/or ensure appropriate safety of the trial participants. The proposed doses could be adjusted based on evaluation of safety, tolerability, and pharmacokinetic data observed in previous panels.
Part 2 was optional and was not conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Part 1 (Mild Cognitive Impairment [MCI] and Mild-to-Moderate Alzheimer's Disease [AD]) Only:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive MK-2214 20 mg as an intravenous (IV) infusion every month (qm) for 3 months (on Days 1, 29, and 57).
Biological: MK-2214
Participants were randomized to receive MK-2214 100 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).
Biological: MK-2214
Participants were randomized to receive MK-2214 500 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).
Biological: MK-2214
Participants were randomized to receive MK-2214 2000 mg as an IV infusion qm for 3 months (on Days 1, 29, and 57).
Biological: MK-2214
Participants were randomized to receive placebo as an IV infusion qm for 3 months (on Days 1, 29, and 57).
Drug: Placebo
IV infusion
IV infusion
Number of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced at least one AE was reported.
Time frame: Up to approximately 297 days
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE was reported.
Time frame: Up to approximately 57 days
Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)
AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after first dose (Day 1).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)
AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after third dose (Day 57).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)
Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after first dose (Day 1).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
Cmax of MK-2214 After Third Dose (Day 57)
Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after third dose (Day 57).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)
Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after first dose (Day 1).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
Tmax of MK-2214 After Third Dose (Day 57)
Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after third dose (Day 57).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)
T1/2 was defined as the apparent half-life of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine t1/2 of MK-2214 in serum after third dose (Day 57).
Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85
Concentration of MK-2214 in CSF was defined as the CSF exposure of MK-2214. A CSF sample was to be collected on Day 85.
Time frame: Day 85
Free Phospho-Tau Concentration in CSF
Concentration of free phospo-tau in CSF was defined as free phospho-tau levels in CSF after study treatment administration (MK-2214 or placebo). A CSF sample was to be collected on Day 85.
Time frame: Day 85
| Milestone | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo |
|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 9 |
| Completed | 6 | 6 | 6 | 5 | 7 |
| Not completed | 1 | 0 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 | 2 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced at least one AE was reported.
| Participants | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 5 | 5 | 4 | 5 | 7 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE was reported.
| Participants | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 0 | 0 | 0 | 0 | 1 |
AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after first dose (Day 1).
| h*µg/L | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1) | 1090000 (855000 to 1390000) | 5730000 (4410000 to 7440000) | 25000000 (19300000 to 32500000) | 200000 (154000 to 259000) |
AUC0-28 was defined as the area under the concentration-time curve from time 0 to 28 days of MK-2214 in serum. Blood samples were collected at prespecified time points to determine AUC0-28 of MK-2214 in serum after third dose (Day 57).
| h*µg/L | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| AUC0-28 of MK-2214 in Serum After Third Dose (Day 57) | 2030000 (1580000 to 2610000) | 13000000 (9990000 to 16800000) | 49800000 (38300000 to 64600000) | 325000 (247000 to 428000) |
Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after first dose (Day 1).
| µg/L | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1) | 5360 (3960 to 7250) | 29600 (21400 to 41100) | 129000 (93200 to 179000) | 980 (707 to 1360) |
Cmax was defined as the maximum concentration of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine Cmax of MK-2214 after third dose (Day 57).
| µg/L | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Cmax of MK-2214 After Third Dose (Day 57) | 7300 (5280 to 10100) | 39400 (28400 to 54600) | 167000 (120000 to 231000) | 1200 (845 to 1710) |
Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after first dose (Day 1).
| hr | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1) | 1.00 (0.50 to 23.97) | 1.29 (0.53 to 2.05) | 1.01 (0.55 to 12.02) | 1.03 (0.12 to 2.00) |
Tmax was defined as the time to maximum serum concentration of MK-2214. Blood samples were collected at prespecified time points to determine Tmax of MK-2214 in serum after third dose (Day 57).
| hr | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Tmax of MK-2214 After Third Dose (Day 57) | 1.03 (0.53 to 3.98) | 3.99 (1.35 to 672.27) | 2.02 (0.52 to 4.07) | 1.00 (0.12 to 4.03) |
T1/2 was defined as the apparent half-life of MK-2214 observed in serum. Blood samples were collected at prespecified time points to determine t1/2 of MK-2214 in serum after third dose (Day 57).
| hr | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57) | 1964.6 ± 23.1 | 1519.5 ± 41.8 | 2016.5 ± 18.0 | 2204.6 ± 16.6 |
Concentration of MK-2214 in CSF was defined as the CSF exposure of MK-2214. A CSF sample was to be collected on Day 85.
| nM | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg |
|---|---|---|---|---|
| Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85 | 0.0487 (0.0258 to 0.0920) | 0.378 (0.200 to 0.714) | 1.13 (0.596 to 2.12) | 0.00655 (0.00347 to 0.0124) |
Concentration of free phospo-tau in CSF was defined as free phospho-tau levels in CSF after study treatment administration (MK-2214 or placebo). A CSF sample was to be collected on Day 85.
| fM | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo |
|---|---|---|---|---|---|
| Free Phospho-Tau Concentration in CSF | 4.1 ± 0.00 | 4.1 ± 0.00 | 4.1 ± 0.00 | — | 13 ± 3.2 |
Collected over Up to approximately 297 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-2214 20 mg | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| MK-2214 100 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| MK-2214 500 mg | 0/6 (0%) | 2/6 (33.3%) | 4/6 (66.7%) |
| MK-2214 4 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Placebo | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| MK-2214 Total | 0/25 (0%) | 3/25 (12%) | 19/25 (76%) |
| Event | MK-2214 20 mg | MK-2214 100 mg | MK-2214 500 mg | MK-2214 4 mg | Placebo | MK-2214 Total |
|---|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/7 | 0/6 | 1/6 | 0/6 | 0/9 | 1/25 |
| Hepatic lesionHepatobiliary disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| Portal vein thrombosisHepatobiliary disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| OsteomyelitisInfections and infestations | 0/7 | 0/6 | 1/6 | 0/6 | 0/9 | 1/25 |
| SepsisInfections and infestations | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| DehydrationMetabolism and nutrition disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| SeizureNervous system disorders | 0/7 | 0/6 | 0/6 | 0/6 | 1/9 | 0/25 |
| Event | MK-2214 20 mg | MK-2214 100 mg | MK-2214 500 mg | MK-2214 4 mg | Placebo | MK-2214 Total |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/7 | 1/6 | 3/6 | 2/6 | 2/9 | 7/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/7 | 0/6 | 0/6 | 2/6 | 0/9 | 3/25 |
| DizzinessNervous system disorders | 0/7 | 1/6 | 0/6 | 2/6 | 1/9 | 3/25 |
| Urinary tract infectionInfections and infestations | 0/7 | 0/6 | 1/6 | 0/6 | 2/9 | 1/25 |
| AnaemiaBlood and lymphatic system disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| Normocytic anaemiaBlood and lymphatic system disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| DyspepsiaGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| NauseaGastrointestinal disorders | 0/7 | 0/6 | 1/6 | 0/6 | 0/9 | 1/25 |
| FatigueGeneral disorders | 0/7 | 0/6 | 0/6 | 1/6 | 0/9 | 1/25 |
| Generalised oedemaGeneral disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/9 | 1/25 |
| Age, Continuous(Years) | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 73.1 ± 9.5 | 68.3 ± 4.3 | 71.2 ± 8.5 | 73.3 ± 3.1 | 68.9 ± 8.2 | 70.9 ± 7.2 |
| Sex: Female, Male(Participants) | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 4 | 3 | 4 | 4 | 18 |
| Male | 4 | 2 | 3 | 2 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 0 | 1 | 4 | 11 |
| Not Hispanic or Latino | 4 | 3 | 6 | 5 | 5 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: MK-2214 20 mg | Panel B: MK-2214 100 mg | Panel C: MK-2214 500 mg | Panel D: MK-2214 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 1 | 0 | 5 |
| White | 6 | 4 | 5 | 4 | 9 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2022 to primary completion in Jul 2025, 33 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 33 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.